Stock Opinions by Karen Firestone, CEO, Aureus Asset Management

Most recent Opinions go here

Be up to date, don’t miss your chance.

BUY

She is overweight and bought more. Retail stores can't find workers and suffer threat. So, Amazon becomes the only alternative in retail. Their retail business is getting another lift higher now.

BUY

Still owns it. The market liked what Meta said on the ad front, where clients can create their own ads with tools that Meta supplies--a game changer.

SELL

She got sick of holding this, because they have trouble with Photoshop--now people can use the tools found in PS elsewhere. She sold before the quarter. Also with Meta, clients can create their own ads using Meta's tools. Adobe hasn't moved fast enough to develop such tools.

BUY

Is defensive and not a target like the pharmas. Abbott is in testing and diagnostics, a steady business reflected in their numbers.

BUY

Her top performer this year. Is a European testing company of food, drugs, make-up and many other products. The US is their biggest customer. 

BUY

Despite being -39% this year, she is holding on and even buying more. UNH has fixable problems, being structural changes, starting with better Medicare/Medicaid reimbursement.

BUY

Is breaking out and their runway is long, given the AI boom.

COMMENT
Reuters/ISOS poll says 53% of American feel the economy is on the wrong track vs. 43% in Jan. 24-26

We had euphoria after the election, but now we're running into a reality where investors are asking what is going to work and who will it work for? Which sectors and industries given the change we see each day in government (i.e. federal agencies). People are worried and concerned what might happen and this is weighing on stocks. Yes, the S&P is hitting a high today, but the market momentum is fading.

BUY

She bought it. The stock was in a decline, though recently come back off its high, so she entered. Also, companies are spending $100 billion on AI, much will go towards NVDA chips that will remain dominant.

BUY

The chart has been choppy and rough, but the last quarter finally showed sales picking up. They've invested a lot on their online platform to the best in the industry. The worst is behind it.

BUY

It keeps hitting new highs, being in the right place over the last 10 years. It's taking a greater market share because more purchasing is going on cards. They have the best technology and will maintain dominance.

BUY

She bought it because the industry has underperformed many years; they're facing several drugs coming off patent, but are developing new drugs they will bring to market. Trades under 9x PE and pays a 4.6% dividend. This industry will benefit greatly from AI.

SELL

She sold it. They made acquisitions she didn't love, though have grown earnings, but missing expectations. She doesn't like their strategy of breaking up the company.

PARTIAL SELL

She was lucky to trim it before earnings. A quality industrial, though sinking today on earnings.

PARTIAL SELL

Has owned it for years and has done exactly what she wanted it to. They're in the health savings business and benefits from a full employment and higher interest rates. Was a big position, so she took some shares off the table.

Showing 1 to 15 of 129 entries